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Introduction
A year ago, the second workshop in this series presented
early clinical experiences with a new group of inhibitors of
Cox-2. Two of these, celecoxib and rofecoxib, are now
marketed in some 30 countries worldwide. Just like last
year’s meeting, this one was organised by Peter Lipsky,
just appointed to the post of Scientific Director of the
National Institute of Musculoskeletal and Skin Diseases
at NIH, Bethesda, MD, USA, together with an interna-
tional study group. This workshop was again very informa-
tive, presenting the latest research results from leading
experts in several fields.
Structure and function of Cox enzymes
Although the crystal structure of the Cox enzymes has
been known in principle for a few years, several function-
ally important features still remain to be explored. Ravi
Kurumbail, working at Searle in St Louis, MO, reported
new crystallographic details from an improved model with
a resolution of 2.15Å. The Cox-2 enzymatic channel is
wider than that of Cox-1, and it has an open side pocket
where the sulphonamide group of the selective inhibitors
can bind. In the region corresponding to the side pocket
the human isoenzymes have four amino acid differences,
the most essential being the 523 position, where Cox-1
has a bulky tyrosine and Cox-2 a valine, which requires
less space. In Cox-2 Kurumbail could show the formation
of five different hydrogen bonds between the selective
inhibitors and the pocket, leading to strong binding. This
reaction requires some time, however, and explains the
time-dependent inhibition observed when testing Cox-2
inhibition with selective inhibitors. He demonstrated that
site-directed mutations in the pocket region resulted in
weaker binding and fewer hydrogen bonds. He also
showed results with a second generation Cox-2 inhibitor
now in phase II/III of development, called valecoxib. This
compound has a Cox-2 selectivity that is more than 10–20
times that of celecoxib, marketed as Celebrex in the US.
After binding the inhibitors are dissociated and the “off”
speed determines the degree of selectivity. All these
experiments are done in enzyme-substrate systems, and
their relevance for in vivo conditions is not proven.
William Smith (Michigan State University, East Lansing,
MI, USA) reported work on the interaction of arachidonic
and related fatty acids with the Cox enzymes. He showed
that substitution of Arg120 with glutamine in Cox-1
reduced its potency by a factor of 1000, whereas the same
substitution in Cox-2 did not affect enzyme activity.
Arg120 anchors arachidonic acid in the Cox-1 channel, but
does not have this function in Cox-2. Eighteen further
sites in Cox-1 bind arachidonic acid, and serve to optimize
its position. Three products are formed from arachidonic
acid: prostaglandin (Pg)G2, 11-HETE and 15-HETE.
This is evidence that arachidonic acid can bind in at least
three different shapes. The usually depicted hairpin shape
is less likely to occur than an L-shape. Smith also
addressed the interesting question of how the metabo-
lized prostanoid leaves the enzyme, and he favored escape
through a bent continuation of the catalytic channel, for
which he showed crystallographic evidence.
Cellular regulation of Cox synthesis
Harvey Herschman (University of California, Los Angeles,
CA, USA) reported recent progress in the understanding
of the molecular basis for activation of the Cox-2 gene,
which he cloned in 1991. It was shown that c-Jun but not
Erk was involved. In other experiments he used osteoblasts
from Cox-2-mutated animals transfected with the pro-
moter element. Activation involved always the CRE
region of the promoter but the IL-6 site was also involved.
This was tested with a number of activators, such as
bFGF (basic fibroblast growth factor), PDGF (platelet-
derived growth factor), PgG2, tumour necrosis factorArthritis Research    Vol 1 No 1 Meeting report
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(TNF)a and IL-1b. The fundamental question of why the
cells have two Cox isozymes is still enigmatic. Thus mast
cells where Cox-2 is inhibited produce no PgE2, despite
having functional Cox-1. Another line of experiments in
progress has aimed at visualizing Cox-2 activation in vivo
in rodents using positron emission tomography (PET)
scanning. For this to work it was necessary to improve res-
olution from 5mm to 1.8mm. This had been achieved by
using Fluorogancyclivir, and Herschman hoped to report
results to this workshop next year.
Timothy Hla (University of Connecticut School of Medi-
cine, Farmington, CT, USA) focused on Cox-2 regulation
at the 3¢ end of the gene. This area has 22 repeats of an
AUUUA motif. These repeats determine the stability of
the mRNA. Glucocorticoids destabilize and IL-1 stabilizes
Cox-2 mRNA. Overexpression of Cox-2, as it occurs in the
rheumatoid synovium, leads to angiogenesis by complex
mechanisms involving both Pg-dependent and other path-
ways and mediated by G-protein-coupled nuclear PPAR
(peroxisome proliferator-activated receptor) family of
receptors. Thus overexpression of Cox-2 is a critical step
in the pathogenesis of tissue damage in rheumatoid arthri-
tis (RA). Similar mechanisms are involved in invasiveness
of malignant tumours.
The mechanism by which Cox-2 might be induced during
tumorigenesis was further investigated by Dan
Beauchamp (Vanderbilt University Medical Center,
Nashville, TN, USA). The key role of the oncogene Ras
and of TGFb1 was demonstrated. TGFb1 is synergistic
with Ras, and stabilizes Cox-2 mRNA, resulting in 20–50-
fold increases in induction, compared to only 3–5-fold
increases by each stimulator. A paradox is that, in tumour
cells, TGFb1 fails to inhibit cell growth. One effect of the
increased Pg production in tumour cells is plasmin activa-
tion, which also requires urokinase plasminogen activator
(uPA). Celecoxib has been shown to inhibit uPA. This
illustrates how elucidation of complex cellular events can
help in devising therapeutic targets.
Biology of arachidonic acid metabolites
Two talks dealt with biological effects of the arachidonic
acid metabolite PGE2. Richard M Breyer (Vanderbilt Uni-
versity Medical Center, Nashville, TN, USA) worked with
PG receptors. Four receptors have been described, EPs
1–4. These mediate different partly overlapping biological
functions. The function of EP2 was studied by using mice
with the EP2 gene knocked out (EP–/–). Such mice
develop normally, but have a slightly elevated blood pres-
sure and produce small litters. They also develop hyper-
tension when exposed to high salt intake, which does not
occur in wild-type mice, and they fail to react with
hypotension to PGE2. The small litter size is linked to a
pre-implantation defect. These results indicate that EP2
could be a putative target for new anti-hypertensive drug
treatment. Thomas M Coffman (Duke University Medical
Center, Durham, NC, USA) further explored the different
tissue distribution of these receptors and how the recep-
tors explain the variety of biological functions of PGE2.
These experiments used the technique of mutating one or
more of the receptors and differing but partly overlapping
functions emerged.
Cox-2 expression in the eye
Kay Brune (University of Erlangen, Germany) is studying
the role of Cox-2 in the eye. He reminded us of the pres-
sure-lowering effect of topical PGs, and of the fact that
30% of patients on chronic glucocorticoid therapy develop
elevated intraocular pressure. In the normal eye Cox-2 is
strongly expressed in the ciliary body and the enzyme is
mostly membrane-associated. Patients with primary open
angle glaucoma (POAG) have subnormal concentrations of
PG in the aqueous humour. In familial glaucoma a gene
defect was located to chromosome 1, to which the Cox-2
gene is also mapped. No Cox-2 gene defect has, however,
been detected in such individuals. Administration of Cele-
brex to two normal individuals resulted in moderate but
significant increases of the intraocular pressure, and in less
diurnal variation. In the discussion Johannes Bijlsma
(Utrecht University, The Netherlands) asked an impor-
tant question: why do patients treated with classical
NSAIDs (nonsteroidal anti-inflammatory drugs) not
develop glaucoma. Brune pointed out that, due to the
non-acidic nature of the new Cox-2 inhibitors, which is in
contrast to the acidic nature of NSAIDs, the Cox-2 drugs
may not penetrate into inflammatory tissue with the same
affinity as the NSAIDs. This may cause a weaker antiin-
flammatory action. The involvement of iNOS (inducible
nitric oxide synthase) was also of possible importance.
Cox-2 and pregnancy
Three speakers addressed the role of Cox-2 in ovulation
and pregnancy. Kumano Dey (University of Kansas
Medical Center, Kansas City, KS, USA), who co-authored
the Cell paper on Cox-2 knockout mice in 1997 (which
among other defects showed infertility in females), has
explored the role of Cox-2 in baboon, skunk, pig and mink
embryos. There is a uniformity in so far as Cox-2 is
involved in ovulation and implantation of the egg and not
least in decidualization. In Cox-2-deficient mice it was
also shown that Cox-2-derived PGI2 was essential for this
process. PGI2 signals via the PPARd receptor family.
Angiogenesis is involved in the process.
Jean Sirois (University of Montreal, Saint-Hyacinthe,
Canada) focused on the molecular control of Cox-2
expression in mammalian ovulation. The so-called Ebox
in the promoter region is essential and ovulation occurs
10h after Cox-2 expression in all species. There is a delay
in expression, however, which differs markedly between
the rat (2–4h), bovine (18h), and equine (30h) follicles,47
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suggesting that Cox-2 plays a role in the control of the
mammalian ovulatory clock.
Finally, James M Trzaskos (Dupont Pharmaceuticals,
Wilmington, DE, USA) studied the intrauterine kinases
after induced decidualization and showed that p38 and not
ERK was necessary for Cox-2 expression in the deeper
stromal cells. Thus the physiologic process of decidualiza-
tion is now known to involve p38, Cox-2, prostacyclin and
PPARd.
Cox-2 and the kidney
The role of Cox-2 in the kidney was addressed by two
investigators, Raymond C Harris (Vanderbilt University
School of Medicine, Nashville, TN, USA) and Marina
Noris (Mario Negri Institute for Pharmacological
Research). Cox-2 expression in the macula densa and its
vicinity is of interest in physiology and pathophysiology as
addressed by Harris. He proposed a working model for
macula densa regulatory interactions where neuronal
(n)NOS, renin, angiotensin II and Cox-2 are the main
players. Partial renal ablation leads to increased expression
of Cox-2 and renin; nNOS also increases Cox-2 and renin.
Renin inhibits angiotensin II, which attenuates Cox-2
expression and augments renin. Captopril dramatically
increases renin formation and plasma renin levels and cele-
coxib reduces this effect. High salt intake induces Cox-2
expression in renal papillary cells. This increased expres-
sion may lead to renal damage, and both Cox-2 inhibition
and p38 inhibition have beneficial effects. Thromboxane
(TX) A2 is a likely mediator inducing increased collagen
deposition and fibrosis.
Noris studies the lupus nephritis model of NZB/W mice
who develop renal disease in a predictable fashion.
Disease onset is accompanied by increased Cox-2 expres-
sion and TX formation. She presented data indicating that
Cox-2 inhibition as well as TXA2 antagonists could ame-
liorate or postpone renal damage in these models. These
results are not uncontroversial, as Noris pointed out. One
caveat is that Cox-2 inhibitors also inhibit the formation of
prostacyclin, which may compromise renal circulation.
Another is that TX antagonists do not work in practice.
Time of administration may be of critical importance. The
subject will no doubt continue to be of central interest in
the near future.
Cox-2 in the lung
In the lung, prostanoids are important in conditions such
as pulmonary hypertension and idiopathic pulmonary
fibrosis. Continuos infusion of a prostacyclin analogue is
now standard therapy in severe pulmonary hypertension.
Marc Peters-Golden (University of Michigan Medical
Center, Ann Arbor, MI, USA) reviewed the field and con-
cluded that Cox-2 expression in the lung may have more
beneficial than adverse effects.
Cox-2 in the pancreas
R Paul Robertson (University of Washington, Seattle, WA,
USA) dealt with the pancreas, where Cox-2 is constitu-
tively expressed in the b-cells. Interleukin (IL)-1 is
known to be important in the pathogenesis of diabetes
and its effect seems to be mediated by PGE2. Selective
inhibitors of Cox-2 can partly ameliorate the deleterious
effects of IL-1 on b-cell function, indicating that it is
mediated by prostanoids via Cox-2.
Cox-2 gastrointestinal tolerance
A novel role for Cox-2 in the gut was proposed by William
F Stenson (Washington University School of Medicine, St
Louis, MO, USA). The gut is abundant with microorgan-
isms of potentially harmful nature, yet no inflammatory
reactions occur normally. This is sometimes termed ‘toler-
ance’. To study the mechanism of this tolerance Stenson
and his colleagues had utilized mice with ablated TCRa
chains and transfected them with TCRa chains specific
for the antigen hen egg-white lysozyme peptide 46–61.
When fed this antigen the mice developed no symptoms.
However if a classical NSAID or the Cox-2 selective cele-
coxib were administered concomitantly with the antigen,
an inflammatory reaction resulting in villous atrophy and
crypt proliferation was elicited. This could be overcome
by administering PGE2. It was concluded that the lamina
propria mononuclear cells produce Cox-2 and the result-
ing prostanoids inhibit the activation of pathogenic T-cells
in the gut wall. An argument against this hypothesis is the
fact that exposure to nonselective NSAIDs, which inhibit
both Cox isozymes, usually does not lead to inflammation.
MAP kinases as putative targets
An interesting approach was presented by Phyllis White-
ley (Roche Bioscience, Palo Alto, CA, USA). The stress-
activated mitogen-activated protein (MAP) kinase p38
(here called MKp38) is involved in a signal transduction
pathway leading to TNF, IL-1 and prostanoid formation.
It is thus upstream from Cox-2. The inhibition of MKp38
showed similar levels of suppression of inflammation and
pain as did Cox-2 inhibitors, but in addition MKp38 inhi-
bition was effective in treating collagen-induced arthritis,
which does not respond to Cox inhibition. MKp38 is an
obvious therapeutic target that will be tested in the near
future.
Clinical impact of Cox-2 inhibition
Relatively little new information on the two recently mar-
keted selective Cox-2 inhibitors emerged. Gregory Bell
(Merck & Co) presented rofecoxib experiences. Its effi-
cacy was comparable to that of strong classical NSAIDs;
gastrointestinal symptoms were close to but not identical
to those induced by placebo. Discontinuation of therapy
in trials was also intermediate. It is known that close to 5%
of patients develop edema and this has led to careful mon-
itoring of renal function. No change in glomerular filtra-tion rate occurred over 12months of exposure in clinical
trials, mostly in osteoarthritis (OA). Radiographic data
showed no difference between diclofenac and rofecoxib.
There were no data on any influence on progression of
spur formation in OA. Importantly, low dose aspirin for
cardiovascular disease was excluded in these trials.
Celecoxib data were reported by John Fort (Searle,
Skokie, IL, USA). This drug has been dispensed in 9
million prescriptions in the USA, corresponding to
perhaps 30% of new NSAID prescriptions, so far without
major reports regarding adverse reactions. The dose of
100mg twice daily was not superior to 200mg daily. It also
appears that a dose of 400mg daily was not more potent
than 200mg; however, the higher dose caused more
adverse reactions.
Perry Halushka (Medical University of South Carolina,
Charleston, SC, USA) drew attention to the potential risk
of TX-related vascular occlusion after selective Cox-2 inhi-
bition, and illustrated this with a couple of case reports.
One patient suffering from scleroderma had developed
pulmonary embolism after 2–4 doses of a Cox-2 inhibitor
and her TXA2 concentration was four times normal.
Patients with an antiphospholipid syndrome may also be at
risk, and vascular occlusions have been seen in connection
with celecoxib therapy. On the other hand, patients with a
tendency to bleed, such as those with hemophilia, have not
been exposed to selective Cox-2 inhibitors.
Addressing the question of the cardiovascular safety of
celecoxib, Robert Makuch (Yale University, New Haven,
CT, USA) had analysed data in Searle’s database of 13000
patient records from 2–24weeks of placebo controlled
trials as well as records for 6000 patients in a two year open
label trial of celecoxib safety. No increased risk for
myocardial infarct or any serious vascular event emerged
from this investigation.
Is Cox-2 expressed in platelets?
Karsten Schör (Heinrich Heine Universität, Düsseldorf,
Germany) provoked the meeting by claiming that platelets
— against all previous evidence — contained Cox-2. He
showed western blots using three different monoclonal
antisera to Cox-2. The majority of experts were sceptical.
Cost effectiveness
James Scheiman (University of Michigan Medical Center,
Ann Arbor, MI, USA) addressed the burning question of
cost effectiveness of the new drugs. Both misoprostol and
omeprazole have been shown to lower but not eliminate
the risk for serious gastrointestinal complications, but cost
effectiveness only occurs if administration can be limited
to high risk patients, and it is doubtful whether this ever
can be achieved. Similar reasoning can be applied to the
new Cox-2 inhibitors when used to treat pain.
Cox-isoenzymes and cancer
Cox-2 is expressed in several cancer forms and the striking
effects of Cox-2 inhibition in experimental familial adeno-
matous polyposis (FAP) was reported at the meeting last
year. Although Cox-2 is firmly linked to tumour pathogen-
esis, a contribution from Cox-1 cannot be excluded.
Luis García Rodríguez (Spanish Center for Pharmacoepi-
demiologic Research, Madrid, Spain) reported a large new
study on the putative protective role of aspirin and
NSAIDs in relation to dose and time of exposure. He had
utilised data from the United Kingdom General Practice
Research Database related to cases of colorectal adenoma
and cancer in patients between the age of 40 and 79. Out
of a population of 900000, 1869 patients were identified
with adenomas and 2002 with cancer, in the period
January 1994 to September 1997. This corresponds to an
incidence of 6.8 and 7.3 per 10000 person years, respec-
tively. The technique used was a prospective population
based nested case control study. Long term users of
NSAIDs were relatively protected. The age adjusted rela-
tive risks ranged between 0.4 and 1.0 and were on average
0.6. Protection was similar with all NSAIDs and occurred
only after 12 months use or longer. Aspirin was in general
less effective, and only if given in doses of 300mg/day or
higher. Glucocorticoids and paracetamol had no protective
influence. It was estimated that 1000 patient years of
exposure would prevent one case of cancer; this exposure
would on the other hand induce 10 gastrointestinal bleed-
ing events. Extensive search of the literature confirmed
that aspirin in doses of 100mg/day or less was not protec-
tive for gastrointestinal cancer (Michael Thun, American
Cancer Society, Atlanta, GA, USA).
Subbaramaich K Dannenberg (Cornell University, Ithaca,
NY, USA) studied the mechanism of tumour induction by
the oncogene HER-2/neu, which is present in 20–30% of
human breast cancer. Cells from 29 patients were trans-
fected with HER-2/neu and half of them responded with
10-fold or more increase in Cox-2 expression. These cells
also overexpressed the upstream c-Jun product and the
MKp38 mentioned above. MKp38 phosphorylates c-Jun
which then induces Cox-2 expression via the CRE site on
the Cox-2 promoter.
Robert Langenbach (National Institute of Environmental
Health Sciences, Research Triangle Park, NC, USA) had
studied skin tumour formation in mice with mutated Cox-
1 and Cox-2 genes. Both deletions inhibited tumour for-
mation but by different mechanisms.
Concluding remarks
This meeting was another impressive testimony to the
exciting evolving biological significance of the cyclo-
oxygenases. The impatient reader may wonder why there
were not more data on clinical effects in rheumatological
Arthritis Research    Vol 1 No 1 Meeting report
48situations. This is probably because the real positioning of
the new agents will require longer periods of exposure.
Safety data, with the exception of anecdotal reports to the
contrary, so far seem encouraging. Tissue penetration of
the non-acidic Cox-2 inhibitors may differ from that of
classical NSAIDs, which may be of significance with regard
to both efficacy and adverse reactions. Cox-2 inhibition
may have a place in tumour prevention, in particular in the
gastrointestinal system, but the data are still vague. No
new information regarding the important field of central
nervous system disease, in particular Alzheimer’s, was
given. This may, in the end, become the most important of
all indications for Cox-2 inhibition, as the age groups at risk
for Alzheimer’s disease are growing at a frightening rate.
The renal role of Cox-2 in health and disease is another
important question, in particular whether Cox-2 inhibition
may be beneficial in lupus nephritis. Will there be a fourth
workshop? The preliminary commercial success as well as
the identification of many fields of unfinished business do
indicate that this would be a good idea.
Author address: Department of Rheumatology, Lund University
Hospital, S-221 85 Lund, Sweden
http://arthritis-research.com/26oct99/ar0101n01
49